Fatal recurrence of autoimmune hemolytic anemia following pentostatin therapy in a patient with a history of fludarabine-associated hemolytic anemia.
Byrd
J C
JC
Department of Medicine, Walter Reed Army Medical Center, Washington, DC, USA.
Hertler
A A
AA
Weiss
R B
RB
Freiman
J
J
Kweder
S L
SL
Diehl
L F
LF
D000743:Anemia, Hemolytic / Q000139:chemically induced*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001327:Autoimmune Diseases / Q000139:chemically induced*; D017809:Fatal Outcome; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D015649:Pentostatin / Q000009:adverse effects*; D012008:Recurrence; D014740:Vidarabine / Q000009:adverse effects / Q000031:analogs & derivatives*
D000970:Antineoplastic Agents; D015649:Pentostatin; D014740:Vidarabine; C024352:fludarabine